Skip to main content
TipRanks
Go Ultimate75% OFF

Kuros Biosciences (0RHR) Share Price & Analysis

3 Followers

0RHR Stock Chart & Stats

CHF 19.43CHF 0.15(0.78%)
At close: 4:30 PM GMT
CHF17.5CHF20CHF22.5Aug 24Sep 7Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
CHF 19.41 - CHF 19.54
52-Week Range
CHF 16.46 - CHF 32.48
Previous Close
CHF 19.28
Volume
N/A
Average Volume (3M)
11.67K
Market Cap
CHF 771.84M
Enterprise Value
CHF 776.03M
Total Cash (Recent Filing)
CHF 7.85M
Total Debt (Recent Filing)
CHF 11.01M
Price to Earnings (P/E)
107.1
Beta
0.98
Next Earnings
Mar 03, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Rapid Revenue Growth

Rapid sales growth shows that Kuros is expanding adoption of its bone-healing products across targeted surgical markets. Continued revenue scale can improve commercial leverage, support investment in capacity, and strengthen the platform for sustained earnings growth.

High Gross Margins

The high gross margin indicates substantial economic value in the product portfolio and provides room to absorb commercialization and development costs. As revenue scales, this margin structure can support operating leverage and a more durable path to profitability.

Commercial And Clinical Traction

Broader distributor reach, rising surgeon utilization, and substantial patient experience indicate strengthening commercial traction rather than isolated product demand. Ongoing clinical studies and published outcomes could further support adoption, institutional confidence, and market-share expansion.

Bears Say

Weak Cash Conversion

Cash generation has lagged the recent earnings improvement, with operating and free cash flow turning negative. If this persists, working-capital needs and investment spending could increase funding sensitivity and constrain the company’s ability to finance growth internally.

Near-Term Margin Pressure

The planned U.S. production ramp and continuing transformation spending may temporarily offset the benefits of scale and operating leverage. This creates execution risk around the timing of margin expansion, particularly while the company is still establishing consistent profitability.

Clinical Evidence Still Developing

Important comparative clinical evidence is still being generated, so the full support for broader claims, payer acceptance, and institutional adoption has not yet been established. Delayed or less supportive results could limit the pace of expansion in new indications.

Kuros Biosciences News

0RHR FAQ

What was Kuros Biosciences’s price range in the past 12 months?
Kuros Biosciences lowest share price was CHF16.46 and its highest was CHF32.48 in the past 12 months.
What is Kuros Biosciences’s market cap?
Kuros Biosciences’s market cap is CHF771.84M.
When is Kuros Biosciences’s upcoming earnings report date?
Kuros Biosciences’s next earnings report is estimated for Mar 03, 2027 (not yet confirmed), which is in 103 days.
How were Kuros Biosciences’s earnings last quarter?
Kuros Biosciences released its earnings results on Aug 13, 2026. The company reported CHF0.06 earnings per share for the quarter, beating the consensus estimate of CHF0.06 by CHF0.001.
Is Kuros Biosciences overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Kuros Biosciences pay dividends?
Kuros Biosciences does not currently pay dividends.
What is Kuros Biosciences’s EPS estimate?
Kuros Biosciences’s EPS estimate is 0.08.
How many shares outstanding does Kuros Biosciences have?
Kuros Biosciences has 39,826,588 shares outstanding.
What happened to Kuros Biosciences’s price movement after its last earnings report?
Kuros Biosciences reported an EPS of CHF0.06 in its last earnings report, beating expectations of CHF0.06. Following the earnings report the stock price went up 3.304%.
Which hedge fund is a major shareholder of Kuros Biosciences?
Currently, no hedge funds are holding shares in GB:0RHR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology